What is the history of Weaver Syndrome?

Weaver Syndrome was first described in 1974 by Dr. David Weaver, who identified the condition through its characteristic features of accelerated growth and distinct craniofacial traits. Since its discovery, medical understanding of Weaver Syndrome has shifted from a clinical diagnosis based solely on physical appearance to a precise genetic diagnosis linked to mutations in the EZH2 gene.

When and how was Weaver Syndrome first identified?

In 1974, Dr. David Weaver and his colleagues published a report describing three children with a pattern of rapid physical growth, advanced bone age, and specific facial characteristics, such as a broad forehead and micrognathia. This initial report established Weaver Syndrome as a recognizable overgrowth disorder, helping clinicians distinguish it from other conditions involving tall stature.

How has our understanding of Weaver Syndrome evolved?

For decades, Weaver Syndrome was diagnosed strictly through physical examination and developmental observation. The landscape changed dramatically in 2011, when researchers identified that heterozygous mutations in the EZH2 gene are the primary cause of Weaver Syndrome. This genetic breakthrough allowed for definitive molecular testing and confirmed that the condition follows an autosomal dominant inheritance pattern.

What were the major milestones in the history of this condition?

• 1974: The inaugural clinical description of Weaver Syndrome is published in the Journal of Pediatrics.


• 2011: Geneticists identify EZH2 mutations as the causative factor for the majority of Weaver Syndrome cases.


• Modern Era: Advanced genomic sequencing now allows for the differentiation of Weaver Syndrome from other overgrowth syndromes like Sotos syndrome.

How has patient advocacy changed for the community?

Historically, families affected by Weaver Syndrome faced isolation due to the rarity of the diagnosis. Today, platforms like DiseaseMaps.org provide a vital space for the community—currently including 6 members—to share lived experiences, manage expectations regarding growth milestones, and advocate for further research into the long-term health implications of EZH2-related disorders.

Next steps

• Consult a clinical geneticist to discuss molecular testing for EZH2 variants.


• Connect with the 6 members of the DiseaseMaps.org Weaver Syndrome community to share resources.


• Regularly screen for developmental milestones and monitor growth patterns with a pediatric endocrinologist.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Weaver Syndrome


• OMIM (Online Mendelian Inheritance in Man): #277590 Weaver Syndrome


• Orphanet: Rare Disease Database (ORPHA:900)


• Gibson et al. (2012), "EZH2 mutations in Weaver syndrome," American Journal of Medical Genetics.